We are very pleased to announce that Medicilon will participate in the XXVII EFMC International Symposium on Medicinal Chemistry. It kicks off on September 4, 2022 in Nice, the Medicilon European team will be present throughout the event. We sincerely invite you to come to our booth #36 and have a discussion with us!
Organizer: EFMC
Date: September 4-8, 2022
Location: Nice, France
The European Federation for Medicinal chemistry and Chemical biology (EFMC) is an independent association founded in December 1969. It has 26 member associations and about 7.500 members. Its biennial EFMC-ISMC is an important symposium in the field of medicinal chemistry and drug discovery. This time it will cover advances in drug discovery in major therapeutic areas, including bacterial and viral infections, with a particular attention to current and emerging viral pandemics, but also neurodegenerative and cardiovascular diseases, rare diseases and cancer. It will also feature most recent advances in new technologies such as the exploitation of RNA as drug target, artificial intelligence in drug discovery, natural products-based drug discovery, DNA encoded libraries applications and the development of covalent drugs, PROTACs and molecular glues. Innovative approaches in medicinal chemistry will be included such as the development of immunomodulating compounds or the application of affinity selection – mass spectrometry for drug discovery.
About Medicilon
Medicilon is an integrated contract research organization (CRO), providing comprehensive one-step new drug R&D for pharmaceutical enterprises and scientific research institutions around the world. We provide one-stop customized R&D solutions ranging from precise drug targeting to IND filing assistance. Deeply integrate R&D experience, constantly climb the peak of R&D technology, and build an integrated innovation service platform for new drug R&D.
Medicilon Drug Discovery Services
Medicilon Drug discovery services include chemistry (synthetic chemistry, medicinal chemistry) and biology. In terms of chemistry, it can undertake multi-dimensional business such as custom synthesis, compound library construction, SAR compound synthesis and screening, compound structure and biological activity optimization.
The medicinal chemistry team deeply cross-integrates chemistry and biology into each project, and flexibly uses the powerful expertise of computational chemistry to aid the compound design process. At the same time, Medicilon extensively uses advanced drug discovery technology, including PROTAC targeted protein degradation technology, ADC antibody drug conjugation technology, etc. Medicilon efficiently promotes customers' drug research and development projects, controls costs, and improves quality!
Innovative Drug R&D Services
Medicilon gathers the popular POI ligands and multiple tissue types of E3 ligase ligands, in addition of established a linker library containing hundreds of linking molecules. Medicilon has established a complete Proteolysis Targeting Chimera (PROTAC) in vitro analysis platform.
Medicilon has undertaken more than 100 major IND application biopharmaceutical projects, including monoclonal antibodies, double antibodies, polyclonal antibodies, ADCs, viral vaccines and fusion proteins. As of May 2022, Medicilon has successfully assisted in the clinical approval of 10 Antibody-Drug Conjugate (ADC) drugs and has multiple ADC projects under development.
mRNA Vaccine Bioanalysis Platform
Medicilon has provided comprehensive support and services for the safety and effectiveness evaluation of various new drugs and vaccines, specifically the research of LNP-mRNA drugs and vaccines. We have accumulated rich experience on this technology; therefore, we establish the bioanalysis platform for mRNA vaccines. Based on the mechanism and characteristics of mRNA vaccines, Medicilon’s Bioanalysis Department has established an evaluation platform covering metabolism and biodistribution, key sequence domain antibodies and antiviral neutralizing antibody titers and the evaluation of effectiveness of cellular immune response.
As the first CRO stock on the Sci-tech Innovation Board, Medicilon is one of the companies that pay attention to AI technology in the industry at the beginning. Currently, Medicilon uses deep neural network machine learning technology to construct a BTK inhibitor drug design model. Medicilon also commits to establishing a molecular design and screening platform for BTK inhibitor drugs, launching “CRO+AI” to accelerate the development of new drugs.
Share：
Online registrationRelevant
news
marketing@medicilon.com
